Protease inhibitors in carcinogenesis: possible sites of action

Genes upregulated in lead-resistant glioma cells reveal possible targets for lead-induced developmental neurotoxicity.

Toxicological sciences : an official journal of the Society of Toxicology·2001

Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis.

Toxicology and applied pharmacology·2001

Reduction of spontaneous mutagenesis in mismatch repair-deficient and proficient cells by dietary antioxidants.

Mutation research·2001

Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts -- a possible mechanism for arsenite's comutagenicity.

Mutation research·2001

Cloning genes whose levels of expression are altered by metals: implications for human health research.

American journal of industrial medicine·2000

Expression cloning for arsenite-resistance resulted in isolation of tumor-suppressor fau cDNA: possible involvement of the ubiquitin system in arsenic carcinogenesis.

Carcinogenesis·1999

Tumor progression in melanoma: the biology of epidermal melanocytes in vitro.

Carcinogenesis; a comprehensive survey·1989

Chromosome alterations in human malignant melanoma.

Carcinogenesis; a comprehensive survey·1989

Genetic background and development of skin tumors.

Carcinogenesis; a comprehensive survey·1989

In vitro models of mutagenesis.

Carcinogenesis; a comprehensive survey·1985

Chromosome abnormalities in human leukemia as indicators of mutagenic exposure.

Carcinogenesis; a comprehensive survey·1985

Retinoblastoma gene: a human cancer recessive (regulatory?) susceptibility gene.

Carcinogenesis; a comprehensive survey·1985

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

European journal of nuclear medicine and molecular imaging·2026

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Gut·2026

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Journal of Crohn's & colitis·2026

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Biochimica et biophysica acta. Reviews on cancer·2026

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Biochimica et biophysica acta. Reviews on cancer·2026

Related Experiment Videos

Protease inhibitors in carcinogenesis: possible sites of action

Related Concept Videos

Genes upregulated in lead-resistant glioma cells reveal possible targets for lead-induced developmental neurotoxicity.

Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: an animal model for arsenic carcinogenesis.

Reduction of spontaneous mutagenesis in mismatch repair-deficient and proficient cells by dietary antioxidants.

Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts -- a possible mechanism for arsenite's comutagenicity.

Cloning genes whose levels of expression are altered by metals: implications for human health research.

Expression cloning for arsenite-resistance resulted in isolation of tumor-suppressor fau cDNA: possible involvement of the ubiquitin system in arsenic carcinogenesis.

Tumor progression in melanoma: the biology of epidermal melanocytes in vitro.

Chromosome alterations in human malignant melanoma.

Genetic background and development of skin tumors.

In vitro models of mutagenesis.

Chromosome abnormalities in human leukemia as indicators of mutagenic exposure.

Retinoblastoma gene: a human cancer recessive (regulatory?) susceptibility gene.

Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation.

Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer.

Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.

Bridging preclinical and clinical efficacy of SIK2/SIK3 inhibition in inflammatory bowel disease through integrated murine, patient-derived models, and phase 2a trial-based analyses.

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.

Related Experiment Videos

Protease inhibitors in carcinogenesis: possible sites of action

Related Concept Videos

Related Articles